Celcuity Inc. (CELC)
$89.85-$3.39 (-3.64%) Today
David DalveyCelcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 3,100,000 | $317.75M |
| Grant or award | 12 | 265,180 | |
| Option exercise | 2 | 2,000 | |
| Bona-fide gift | 4 | 53,102 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
35 Form 4 filings on record, the earliest from Oct 25, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Dalvey | Open-market sale | Common Stock | 3,137 | $44.36 | $139K | |
| David Dalvey | Open-market sale | Common Stock | 4,163 | $45.24 | $188K | |
| David Dalvey | Open-market sale | Common Stock | 2,025 | $46.05 | $93K | |
| David Dalvey | Open-market sale | Common Stock | 57,044 | $43.30 | $2.47M | |
| David Dalvey | Open-market sale | Common Stock | 22,377 | $44.36 | $993K | |
| David Dalvey | Open-market sale | Common Stock | 16,438 | $45.29 | $744K | |
| David Dalvey | Open-market sale | Common Stock | 4,141 | $46.05 | $191K | |
| David Dalvey | Grant or award | Stock Option (right to buy) | 14,048 | $0.00 | - | |
| Richard Nigon | Grant or award | Stock Option (right to buy) | 14,048 | $0.00 | - | |
| Leo Furcht | Option exercise | Common Stock | 250 | $3.60 | $900 | |
| Leo Furcht | Option exercise | Employee Stock Option (right to buy) | 250 | $0.00 | - | |
| Richard E. Buller - Director | Open-market sale | Common Stock | 350 | $16.25 | $6K |
This is as far as the anonymous view goes. Create a free account for all 35 CELC filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Celcuity Inc. (CELC) had 13 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for CELC runs to 35 Form 4 filings, the earliest from 2024-10-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CELC were filed in the last 90 days. 4 purchases are on record for this company.
2 insider sales of CELC were filed in the last 90 days, totaling $317.75M.
This page tracks CELC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CELC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
